Ezurpimtrostat

Generic Name: Ezurpimtrostat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₁ClN_₄

CAS Number: 1914148-72-3

Unique Ingredient Identifier: MS6LGW5JFK

Associated Conditions: -

Associated Therapies: -

Clinical Trials

FDA Grants Orphan Drug Designation to Ezurpimtrostat for Hepatocellular Carcinoma Treatment

The FDA granted orphan drug designation to ezurpimtrostat (GNS561) for hepatocellular carcinoma (HCC) treatment. Genoscience Pharma's phase 2b trial combines ezurpimtrostat with atezolizumab/bevacizumab, aiming to improve HCC outcomes. Ezurpimtrostat, a PPT-1 inhibitor, shows promise in liver cancer treatment, with phase 1b trial data indicating safety and reduced PPT1 expression in liver cancer tissues.

Related Clinical Trials:

Study of GNS561 in Patients With Liver Cancer

Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy